Cancer experts urge "cautious optimism" as patients enquire about ...

ETHealthworld.com - 08 Jun 2022
The top Indian cancer experts felt that even after the success of Dostarlimab medical trial, the cost of this immunotherapy drug is going to be a majo..

Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers

Cancer Network - 24 Apr 2024
Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers ...

Dostarlimab/Chemo Receives FDA Priority Review for Expanded Indication in Endometrial Cancer

OncLive - 24 Apr 2024
Dostarlimab/Chemo Receives FDA Priority Review for Expanded Indication in Endometrial Cancer ...

FDA Grants Priority Review for Expanded Indication of GSK's Jemperli

BioPharm International - 24 Apr 2024
FDA Grants Priority Review for Expanded Indication of GSK's Jemperli ...

Dostarlimab, Chemotherapy Combination is Cost Effective for Endometrial Cancer

DocWire News - 24 Apr 2024
Dostarlimab, Chemotherapy Combination is Cost Effective for Endometrial Cancer ...

Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell ...

Nature.com - 11 Nov 2023
Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell ... ...

Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer

ScienceDirect.com - 18 Oct 2023
Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer ...

Woman's bowel cancer disappears thanks to 'miracle' drug

BBC.com - 06 Oct 2023
Woman's bowel cancer disappears thanks to 'miracle' drug ...

FDA OKs Dostarlimab Plus Chemo for Endometrial Cancer

Medscape - 31 Jul 2023
FDA OKs Dostarlimab Plus Chemo for Endometrial Cancer ...

Dostarlimab given NICE go-ahead in first-line combination treatment for endometrial cancer

Hospital Healthcare - 14 Mar 2024
Dostarlimab given NICE go-ahead in first-line combination treatment for endometrial cancer ...

Dostarlimab Improves OS in Advanced, Recurrent Endometrial Cancer

Cancer Therapy Advisor - 16 Mar 2024
Dostarlimab Improves OS in Advanced, Recurrent Endometrial Cancer ...

Matthew A. Powell, MD, on Endometrial Cancer: Overall Survival Update on Dostarlimab-gxly Plus Chemotherapy

The ASCO Post - 27 Mar 2024
Matthew A. Powell, MD, on Endometrial Cancer: Overall Survival Update on Dostarlimab-gxly Plus Chemotherapy ...

Dostarlimab/Chemo Yields “Unprecedented” OS in dMMR Endometrial Cancer

Cancer Network - 20 Mar 2024
Dostarlimab/Chemo Yields “Unprecedented” OS in dMMR Endometrial Cancer ...

Dostarlimab Plus Chemo Demonstrates Survival Advantage in Advanced Endometrial Cancer

OncLive - 16 Mar 2024
Dostarlimab Plus Chemo Demonstrates Survival Advantage in Advanced Endometrial Cancer ...

Dr Eskander on Pembrolizumab Plus Chemo in Advanced/Recurrent Endometrial Cancer

OncLive - 24 Apr 2024
Dr Eskander on Pembrolizumab Plus Chemo in Advanced/Recurrent Endometrial Cancer ...

Dostarlimab/Niraparib Improves PFS Outcomes in Advanced Endometrial Cancer

Cancer Network - 20 Dec 2023
Dostarlimab/Niraparib Improves PFS Outcomes in Advanced Endometrial Cancer ...

NICE Recommends Dostarlimab Plus Chemo in MSI-High/dMMR Endometrial Cancer

OncLive - 05 Mar 2024
NICE Recommends Dostarlimab Plus Chemo in MSI-High/dMMR Endometrial Cancer ...

Dostarlimab Combo Significantly Improves PFS in Advanced Endometrial Cancer

Cancer Network - 16 Nov 2023
Dostarlimab Combo Significantly Improves PFS in Advanced Endometrial Cancer ...

Dostarlimab Combo Yields Efficacy Results in Advanced NSCLC

Cancer Network - 20 Oct 2023
Dostarlimab Combo Yields Efficacy Results in Advanced NSCLC ...

CHMP Recommends Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced/Recurrent Endometrial Cancer

OncLive - 16 Oct 2023
CHMP Recommends Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced/Recurrent Endometrial Cancer ...

Dostarlimab